Active Ingredient History

NOW
  • Now
Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. The drug completed a phase II trial for primary biliary cholangitis. "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus." A phase III trial in patients with PBC also found reduced pruritus and improved liver biochemistry, despite being terminated early.   Wikipedia

  • SMILES: CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(OCC(=O)O)c(C)c2
  • InChIKey: JWHYSEDOYMYMNM-QGZVFWFLSA-N
  • Mol. Mass: 444.47
  • ALogP: 5.05
  • ChEMBL Molecules:
More Chemistry
(2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2h-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid | mbx-8025 | rwj-800025 | seladelpar

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue